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Background: Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease predominantly
affecting young women. Some of these patients develop lymphedema of the lower extremities
and buttocks; however, neither the exact frequency of LAM-associated lymphedema nor the
clinical features of such patients is well delineated.
Objectives: Todocument the frequency, features, and treatmentofLAM-associated lymphedema.
Methods: We reviewed all medical records of patients listed in the Juntendo University LAM regis-
try for the 30 years preceding August 2010.
Results: Of 228 patients registered with a diagnosis of LAM, eight (3.5%) had LAM-associated lym-
phedema of the lower extremities. All were females with sporadic LAM, and their mean age when
diagnosed was 32.5 years (range 23e44). Lymphedema of the lower extremities was the chief or aespiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, 2-1-1
apan. Tel.: þ81 3 5802 1063; fax: þ81 3 5802 1617.
o.ac.jp (Y. Hoshika).
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1254 Y. Hoshika et al.prominent presenting feature in five of these LAM patients. CTscans showed that all eight patients
had enlarged lymph nodes (lymphangioleiomyomas) in the retroperitoneum and/or pelvic cavity.
Yet, cystic destruction of the lungs was mild in four patients, moderate in two and severe only in
two. Seven of these patients were treated by administering a fat-restricted diet and complex
decongestive physiotherapy, and four received a gonadotropin-releasing hormone analog. With
this combined protocol, all eight patients benefitted from complete relief or good control of the
lymphedema.
Conclusions: Lymphedema is a rare complication of LAM and may be associated with axial
lymphatic involvement or dysfunction rather than severe cystic lung destruction. The combined
multimodal treatments used here effectively resolved or controlled LAM-associated lymphedema.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The neoplastic disease lymphangioleiomyomatosis (LAM)
predominantly affects the lungs of young women but also
occurs along the axial lymphatic systems, including lymph
nodes in the mediastinum, retroperitoneum, pelvic cavity,
and thoracic ducts. This rare disease is characterized by the
proliferation of LAM cells (smooth muscle-like cells) and
LAM-associated lymphangiogenesis. LAM cells are consid-
ered to be transformed by abnormalities of either the TSC1
or TSC2 tumor suppressor gene.1,2
The clinical manifestations of LAM include exertional
dyspnea, spontaneous pneumothorax, hemosputum,
chylous pleural effusion, and symptoms associated with
extrapulmonary involvement.3 The representative extrap-
ulmonary problems are chylous ascites and lymphangio-
leiomyomas (of axial lymph nodes and lymphatics) in the
retroperitoneum and pelvic cavity. Lymphangioleiomyomas
usually do not exhibit symptoms. However, some LAM pa-
tients may feel unexplained pain or distension and also
lymphedema of the lower extremities and buttocks.
Lymphedema is the result of protein-rich interstitial
volume overload, secondary to lymph drainage failure in
the face of normal capillary filtration.4 This state occurs
when there is an inherent defect within the lymph-carrying
conduits, termed “primary lymphedema,” or damage ari-
ses, termed “secondary lymphedema” (e.g., pressure from
tumors, scar tissue after radiation, surgical removal of
lymph nodes, etc.). Because lymphedema is often difficult
to cure, the result may be such psychological sequelae as
frustration, distress, depression and anxiety.5,6 For many of
these patients, the quality of life becomes impaired.
Since the exact frequency of LAM-associated lymphe-
dema and clinical features of LAM patients whose condition
is complicated by lymphedema are not well delineated, we
retrospectively reviewed our LAM registry. The purpose was
to understand and alleviate the troubling outcome of this
disease.
Methods
Identification of patients with LAM-associated
lymphedema
As of August 2010, we retrospectively reviewed medical re-
cords of patients with LAM who visited the Department ofRespiratoryMedicine, JuntendoUniversity Hospital, andwere
recorded in the Juntendo LAM registry since 1980. We found
LAM-associated lymphedemaof the lowerextremities in eight
(3.5%) of 228 LAM patients. We then analyzed followup nota-
tions from their medical records: that is, age at the diagnosis
of LAM, symptoms, radiological findings on scans from the
chest to pelvic cavity based on either computed tomography
(CT) or magnetic resonance imaging (MRI), and treatment for
LAM and LAM-associated lymphedema. Lymphedema was
diagnosed from physical examination, imaging (lympho-
scintigraphy, MRI, CT and/or ultrasonography) and exclusion
of other diseases that cause edema in the lower extremities.
Grading of cystic lung destruction
The severity of cystic lung destruction due to LAM was
assessed visually according to the modified Goddard scoring
system.7 Six images were selected (bilateral lung field in
the upper, middle, and lower axial lung slices) and
analyzed. Each image was classified as normal (score 0),
5% affected (score 0.5), 25% affected (score 1), 50%
affected (score 2), 75% affected (score 3), >75% affected
(score 4), giving a minimum score of 0 and maximum of 4.
An average score of all images was considered as a repre-
sentative value of the severity of cystic destruction (mild,
score <1; moderate, 1e2.5; and severe, >2.5).
Classification of lymphedema
The severity of lymphedema was determined from classi-
fications of the International Society of Lymphology8 and is
summarized briefly as follows. Stage 0 refers to a latent or
sub-clinical condition in which swelling is not evident
despite impaired lymph transport. Stage I represents an
early period of the condition when the accumulated fluid is
relatively high in protein content but subsides with limb
elevation. Pitting may occur in stage I lymphedema. Stage II
signifies that limb elevation alone rarely reduces tissue
swelling, and pitting is manifested routinely. Stage III en-
compasses lymphostatic elephantiasis without pitting but
includes trophic skin changes.8
Complex decongestive physiotherapy (CDP)
We performed complex decongestive physiotherapy (CDP),
which is a two-phase noninvasive therapeutic regimen,
Lymphedema features in patients with lymphangioleiomyomatosis 1255according to the study reported by Ko et al.9 Briefly,
the first phase treatment consists of manual lymph
massage (MLM), compression therapy (multilayered inelas-
tic compression bandaging/elastic stocking), remedial ex-
ercises, and skin care. The phase two treatment focuses on
continuous self-care at home by means of daytime elastic
stocking compression, MLM, and continued exercises. Since
some LAM patients had advanced lung involvement or were
complicated with chylous pleural effusion, chylous ascites,
or both, some components of the first phase treatment
were needed to be modified (the intensity and duration of
MLM, type and material of bandaging, degree of compres-
sion applied by elastic garments, etc.) or customized
(exclusion of compression therapy and remedial exercise),
depending on the patient’s clinical condition.
Results
Prevalence and clinical features of LAM-associated
lymphedema
We reviewed medical records of 228 patients with LAM (203
with sporadic LAM and 25 with TSC-LAM) who visited our
hospital from 1980 to August 2010. Among them, eight fe-
male patients (3.5%) were identified as having LAM-Table 1 Clinical features of study population with LAM-associa
Patient #1 Patient #2 Patient #3 Pati
Registry number JUL112 JUL127 JUL130 JUL
Age at the diagnosis
of LAM
28 27 40 35
Age at the onset of
lymphedema
28 27 44 37
History of PTX e e þ e
Presenting feature Lymphedema Lymphedema PTX DOE
Site of lymphedema Bilateral LE Right LE Left LE Righ
Butt
Stage of lymphedema
before treatment 2 2 2 2
after treatment 0 0 0 0
Serum VEGF-D
(pg/ml)
1357 6080 10,900 16,8
Severity of cystic
destruction
on chest CT
Mild Severe Moderate Seve
Lymphangio-
leiomyomas
R R R þ Pv R þ
Chylous pleural
effusion
e þ e e
Chylous ascites e þ þ þ
Angiomyolipoma e e Left kidney e
Treatment FRD, CDP FRD, CDP,
GnRH, HOT
FRD, CDP,
GnRH
FRD
GnR
Abbreviations: CDP, complex decongestive physiotherapy; DOE, dysp
releasing hormone analog; HOT, home oxygen therapy; LE, lower e
upper abdominal region of retroperitoneum; and Pv, lymphangioleiomassociated with lymphedema in the lower extremities and
buttocks (Table 1). All 8 LAM patients were sporadic LAM. In
contrast, none of TSC-LAM in our cohort complicated LAM-
associated lymphedema in the lower extremities and
buttock. One TSC-LAM patient with lymphedema in the
lower extremities was excluded since it was due to the
surgical resection of intrapelvic tumor (uterine anigo-
sarcoma).10 The patients’ mean age at the diagnosis of LAM
was 32.5 years (range 23e42), and their mean age at the
onset of lymphedema was 33.4 years (range 23e42).
Notably, lymphedema of the lower extremities was an
important determinant or confirming factor in the diagnosis
of LAM for five patients; the remaining three patients had
lymphedema transiently or occasionally during their dis-
ease course. Usually, the lymphedema occurred in the
lower limbs (seven of eight patients) with the left leg more
frequently involved than the right, and two patients had
these swellings in bilateral lower extremities. Patient #6
(JUL216, 42-years-old) had lymphedema of her left thigh
with a skin color change that induced her to seek a medical
evaluation and eventually led to the diagnosis of LAM
(Fig. 1). Two patients {patient #4 (JUL181) and patient #5
(JUL213)} had lymphedema in the buttocks as well as lower
extremities. Patient #7 (JUL221) had transient lymphedema
around the left lower abdominal area only when she wore
tight underwear (Fig. 2B). The severity of lymphedema wasted lymphedema.
ent #4 Patient #5 Patient #6 Patient #7 Patient #8
181 JUL213 JUL216 JUL221 JUL129
23 42 33 32
23 42 34 32
þ e e þ
Lymphedema Lymphedema Medical
checkup
Lymphedema
t LE
ock
Bilateral LE
Buttock
Left LE Lower
abdomen
Left LE
2 2 1 2
1 1 0 0
00 10,869 7398 1904 3010
re Moderate Mild Mild Mild
Pv Inguinal R þ Pv Pv R þ Pv
þ e e e
þ e e e
e e e e
, CDP,
H, HOT
FRD, CDP,
GnRH, HOT
FRD, CDP Instruction
only
FRD, CDP
nea on exertion; FRD, fat-restricted diet; GnRH, gonadotropin-
xtremity; PTX, pneumothorax; R, lymphangioleiomyomas in the
yomas in the pelvic cavity.
Figure 1 A representative portrait of LAM-associated lymphedema (patient #6, JUL216). Here, the left thigh was swollen, and inner
side of its proximal portion showed rubor (A). Ultrasonography of both thighs revealed increased intensity and widening of the
subcutaneous layer only in the left thigh (B). In panel B, the scan on the left illustrates the right thigh, and that on the right pictures
the left thigh, supporting the diagnosis of lymphedema (stage 2). After CDP, lymphedema of left thigh decreased from stage 2 to 1 (C).
1256 Y. Hoshika et al.classified as stage 2 in seven of these eight patients; only
patient #7 was at stage 1. Lymphoscintigraphy was per-
formed on three patients and enabled the identification of
a blockade that impeded normal axial lymphatic flow as
shown in the representative example appears of Fig. 3.Figure 2 Representative images of lymphangioleiomyomas in th
(patient #7, JUL 221). Computed tomography of the pelvic cavity a
lymphangioleiomyomas along the left internal iliac vessels (A). T1
strated thickening and fluid accumulated in the subcutaneous tissuClinical features of patients with LAM and
associated lymphedema
The pulmonary and extrapulmonary findings of LAM as well
as treatments administered for LAM and LAM-associatede pelvic cavity and lymphedema of the lower abdominal skin
fter intravenous injection of contrast material revealed cystic
-weighted MRI axial images without contrast material demon-
e of the left lower abdominal skin (B).
Figure 3 Lymphoscintigraphy of the lower extremities (patient #5, JUL213). This lymphoscintigram scanned 60 min after the
subcutaneous injection of 99mTc-labeled human serum albumin (99mTc-HAS) at instep (A, left and B, right) revealed a marked
dermal backflow of 99mTc-HAS due to a blockade of the normal axial lymphatic flow. A: left lower extremity with two differentially
gained-images. B: right lower extremity.
Lymphedema features in patients with lymphangioleiomyomatosis 1257lymphedema are summarized in Table 1. With respect to
findings, the extent of cystic destruction of the lungs was
mild in four patients, moderate in two and severe in two.
Two patients {patient #2 (JUL127) and patient #5 (JUL213)}
showed ground glass attenuation of the lungs suggesting
lymphedema. However, there was no correlation between
the severity of cystic destruction of the lung and LAM-
associated lymphedema. All eight patients had lym-
phangioleiomyomas (enlargements of lymph nodes and/or
lymphatics): seven patients had this condition in the ret-
roperitoneum from an upper abdominal area to the pelvic
cavity (Fig. 2A) but only patient #5 was similarly affected in
the right inguinal area. Chylous pleural effusions were
present in two patients and chylous ascites in four of them.
Moreover, two patients suffered chylous pleural effusion
and also ascites. An angiomyolipoma was evident in only
one patient {patient #3 (JUL130)}. Measurement of the
serum vascular endothelial growth factor (VEGF-D) showed
a concentration of more than 800 pg/ml, indicating a
possible diagnosis of LAM (Table 1).
Treatment for these patients varied over the long term
of this study. Seven patients were treated with a fat-
restricted diet (FRD) and complex decongestive physio-
therapy (CDP). Four received monthly subcutaneous
injections of gonadotropin-releasing hormone (GnRH)
analog. The CDP, which was administered to seven
patients, provided complete relief or substantial control
of their lymphedema (Fig. 1B). For patient #7 (JUL221),
no specific treatment was required, since wearing less
restrictive underwear was enough to resolve her
lymphedema.Discussion
For the present study, we established the frequency of
LAM-associated lymphedema over a 30-year-period in one
hospital and analyzed the clinical features of patients
whose LAM was complicated with lymphedema. Lymphe-
dema was noted in 3.5% (8 of 228) of these LAM patients
and was the main or at least an important presenting
symptom of LAM in five of the eight patients. Therefore,the frequency of lymphedema as a presenting feature of
LAM in this group was 2.2% (5/228). In none of these pa-
tients did the severity of lymphedema exceed the classifi-
cation of stage 2 or less. Prior to our study, only three case
reports about LAM-associated lymphedema of the lower
extremities appeared in the literature,11e13 and its exact
incidence remained unknown.
The diagnosis of LAM as an underlying cause of lym-
phedema is often challenging. Generally, secondary lym-
phedema is caused by axillary, pelvic or inguinal lymph
node dissection and/or radiation for the treatment of
malignancy or infections, those diseases or conditions
eventually resulting in the obstruction of lymphatics.
Accordingly, the diagnosis of secondary lymphedema would
not be difficult if symptoms or a past history indicated an
impact on lymphatic drainage. Similarly, physical findings
such as non-pitting edema and Stemmer sign would serve as
clues. Furthermore, secondary lymphedema typically in-
volves a single limb, whereas more widespread involvement
may be seen in primary hereditary lymphedema.14 In our
study, LAM was at an early stage (mild degree), most often
with unremarkable physical findings. In 25% of these pa-
tients, lymphedema developed in both lower extremities.
Therefore, it is worth emphasizing that here and else-
where, ultrasonography and MRI have been useful for
diagnosing the lymphedema and that lymphoscintigraphy
helped to delineate the functional and physiological
derangement of lymphatic flow in the affected areas (Figs.
1e3).14e16 However, even if we can establish the diagnosis
of lymphedema, LAM would not be considered as an un-
derlying disease unless characteristic LAM-related
symptoms and findings such as exertional dypnea, pneu-
mothorax, chyle leak, etc., are present. Instead, lym-
phomas or soft tissue neoplasms would most likely be
suspected, since enlarged lymph nodes (lymphangioleio-
myomas) mimicking abdominal tumors can be demon-
strated in the retroperitoneum, pelvic cavity, or inguinal
area. Indeed, all eight LAM patients with lymphedema in
their lower extremities or lower abdomen had lym-
phangioleiomyomas that were then extirpated completely
in the three patients (patients #1, #2, and #8) whose clin-
ical diagnoses suggested soft tissue neoplasm or lymphoma.
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phedema and its mechanism(s) remain unknown. LAM is a
neoplastic disease, characterized by both the proliferation
of LAM cells and LAM-associated lymphangiogenesis,17,18
the latter presumably mediated by VEGF-D produced by
LAM cells.19 Serum VEGF-D concentration was reported to
be a good biomarker for lymphatic involvement in LAM20
and indeed, five of eight patients in our study population
showed very high serum VEGF-D concentration (>5000 pg/
ml). Although the number of LAM patients analyzed here
was small, no apparent correlation existed among serum
VEGF-D level, extent of lymphangioleiomyomas, and site or
stage of lymphedema.
Although the existence of lymphangioleiomyomas does
not always lead to a LAM-associated lymphedema in the
patient’s lower extremities, subclinical dysfunction of axial
lymphatics is clearly implied. Actually, the lymphedema
around patient #7’s left thigh and buttocks could be
attributed to the restriction of tight clothing, since loos-
ening her underwear resolved the lymphedema without
further treatment. Patient #4 (JUL181) experienced lym-
phedema around the right buttock and thigh only after an
abdominal bandage was applied to gently squeeze out
chylous ascites. Even these few cases, though, illustrate
the increased amount of subcutaneous lymphatic flow
bypassing the usual axial lymphatic route with impaired
drainage. Supporting this notion, lymphoscintigraphy
clearly delineated a dermal lymphatic flow in patient #5
(JUL213) possibly due to a blockade of lymphatic flow
draining into an axial lymphatics in the pelvic cavity from
lower extremities by an inguinal lymphangioleiomyoma
(Fig. 3). Furthermore, subclinical lymphatic dysfunction has
been supported by radiologic findings that the size of lym-
phagioleiomyomas undergoes dramatic diurnal variation,
i.e., enlargement in the afternoon resulting from increased
lymphatic flow after physical activity in the morning.21,22
Lymphedema is often difficult to treat, particularly if
not diagnosed at an early stage.23 In general, subcutaneous
tissue becomes fibrotic and then spreads circumferentially
if treatment is not initiated. Eventually, the involved skin
becomes hyperkeratotic, hyperpigmented, and papilloma-
tous or verrucous with increased skin turgor.6 The approach
to managing lymphedema is largely dependent upon phys-
iotherapeutic techniques. The term complex decongestive
physiotherapy (CDP) refers to an empirically derived,
multicomponent program that is designed to reduce the
degree of lymphedema and to maintain the health of the
skin and supporting structures.24e26 Some evidence in-
dicates that this approach stimulates lymphatic transport
and facilitates the dispersal of retained interstitial pro-
teins. Seven patients reviewed here were treated with both
CDP and FRD. Once lymphedema was ameliorated or
completely resolved, the condition was sufficiently self-
managed by CDP alone except for the four patients (pa-
tients #2e#5) with chylous effusions. GnRH therapy was
added to the regimen of these four patients, and FRD
continued. Although a controversy still existed regarding
the effect of hormone therapy (estrogen-depleting treat-
ment) on LAM, we added GnRH therapy to the regimen of
these four patients who had chylous effusion to stabilized
LAM and ameliorate chylous effusion. For all eight of these
patients, lymphedema was mitigated completely or well-controlled with CDP, GnRH therapy, and FRD. An addi-
tional possibility comes from recent evidence that siroli-
mus, a mTOR inhibitor, stabilizes lung function27 and causes
chylous effusion to subside.28 Similarly, Chachaj et al. re-
ported the successful treatment of lymphedema, chylous
ascites, and pleural effusion with sirolimus.13 However, our
combined multimodal approach is likely to be a choice for
LAM-associated lymphedema without chylous effusion,
particularly when sirolimus treatment is contraindicated.
In conclusion, this is the first review, to our knowledge,
of the frequency of LAM-associated lymphedema and its
clinical features. In even this small population of LAM pa-
tients, lymphedema appears to be a very important pre-
senting feature that signals the possibility of LAM as an
underlying disease. The dysfunction of axial lymphatics,
undoubtedly caused by proliferation and infiltration of LAM
cells along those sites, as well as the high level of serum
VEGF-D quantified here are significant factors in the
occurrence of lymphedema, but the reason why all LAM
patients with these factors do not have lymphedema is
unknown. The combined multimodal treatments docu-
mented in this analysis were effective for resolving or
controlling lymphedema in patients with LAM.
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